Nyrada Inc
Research Nyrada Inc (NYR) on Bullrun: market cap AUD 184.08M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNYR
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 184.08M
- Financial periodFY2025
- Net income-AUD 4.85M
- Free cash flow-AUD 5.05M
Valuation Snapshot
latest market cap is AUD 184.08M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 4.85M | -AUD 5.05M | n/a | -0.02 | AUD 2.93M | n/a | AUD 3.58M |
| FY2024 | n/a | -AUD 1.39M | -AUD 766.30K | n/a | -0.01 | AUD 4.77M | n/a | AUD 5.05M |
| FY2023 | n/a | -AUD 7.78M | -AUD 7.20M | n/a | -0.05 | AUD 3.71M | n/a | AUD 4.26M |
| FY2022 | n/a | -AUD 3.96M | -AUD 2.93M | n/a | -0.03 | AUD 10.82M | n/a | AUD 11.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | AUD 184.08M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Nyrada Inc
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nyrada Inc's market cap?
Nyrada Inc's market capitalization is AUD 184.08M.
What does Nyrada Inc do?
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.